Sign in

    Erik Lavington

    Senior Research Associate at Mizuho Financial Group, Inc.

    Erik Lavington is a Senior Research Associate at Mizuho Financial Group, Inc., where he specializes in biotechnology equity research and analysis. With a demonstrated focus on innovative biotech firms, he has covered companies such as Kura Oncology, providing analytical insights to institutional clients and helping to drive investment decisions. Lavington previously served as VP & Biotechnology Analyst at BTIG, adding depth to his expertise in the sector, and transitioned to his current role at Mizuho where he is recognized for detailed due diligence and strong sector knowledge. He holds FINRA securities licenses and maintains a robust professional standing as an equity research associate in the life sciences domain.

    Erik Lavington's questions to Kura Oncology (KURA) leadership

    Erik Lavington's questions to Kura Oncology (KURA) leadership • Q2 2025

    Question

    Erik Lavington, on for Salveen Richter, asked for Kura's thoughts on the potential launch ramp for Zifdomenib in relapsed/refractory NPM1-mutant AML and whether a 'warehousing' of patients might occur, unlike what was seen for KMT2A-rearranged AML.

    Answer

    Chief Commercial Officer Brian Powl explained that the company is not providing specific launch ramp guidance but does not expect a large bolus or 'warehousing' of patients. He reasoned that this is an elderly, heavily pretreated population with a high unmet need and short life expectancy, making it unlikely for patients to wait for a new therapy.

    Ask Fintool Equity Research AI